Skip to content

PBMC inflammation assay

Human peripheral blood mononuclear cells (PBMCs) are presented with beads coated in CD3 & CD28, and exposed to IL-23 in the medium, to induce an inflammatory response, detected as an increase in IL-17 secretion. Your compound is tested for its ability to inhibit this inflammatory response, measured as an inhibition of IL-17 release. Cellular viability is also assessed, as a measure of general compound cytotoxicity.

Download the assay protocol.

The PBMC IL-17 assay process

The assay utilizes primary human Peripheral Blood Mononuclear Cells (PBMC) seeded at 130000 cells/well in a 384-well microtiter plate and stimulated using CD3 & CD28 antibodies and IL-23 to induce increased secretion of IL-17. The test molecule is added in different concentrations and after 72 hours the IL-17 levels, as well as the cell viability are measured as the final end point.

Scroll to top